CN101437805B - 苯基氨基-苯并噁唑取代的羧酸，其生产方法及其用途 - Google Patents

苯基氨基-苯并噁唑取代的羧酸，其生产方法及其用途 Download PDF

Info

Publication number
CN101437805B
CN101437805B CN2007800162659A CN200780016265A CN101437805B CN 101437805 B CN101437805 B CN 101437805B CN 2007800162659 A CN2007800162659 A CN 2007800162659A CN 200780016265 A CN200780016265 A CN 200780016265A CN 101437805 B CN101437805 B CN 101437805B
Authority
CN
China
Prior art keywords
compound
formula
alkyl
medicine
administered together
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800162659A
Other languages
English (en)
Chinese (zh)
Other versions
CN101437805A (zh
Inventor
E·德福萨
M·弗尔曼
T·克拉邦德
V·德罗素
G·黑斯勒
S·施滕格林
G·哈施克
A·赫林
S·巴托施克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SRL
Original Assignee
Sanofi Aventis SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis SpA filed Critical Sanofi Aventis SpA
Publication of CN101437805A publication Critical patent/CN101437805A/zh
Application granted granted Critical
Publication of CN101437805B publication Critical patent/CN101437805B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2007800162659A 2006-05-11 2007-04-30 苯基氨基-苯并噁唑取代的羧酸，其生产方法及其用途 Expired - Fee Related CN101437805B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102006021878.7 2006-05-11
DE102006021878A DE102006021878A1 (de) 2006-05-11 2006-05-11 Phenylamino-benzoxazol substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
PCT/EP2007/003806 WO2007131622A1 (de) 2006-05-11 2007-04-30 Phenylamino-benzoxazol substituierte carbonsäuren, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel

Publications (2)

Publication Number Publication Date
CN101437805A CN101437805A (zh) 2009-05-20
CN101437805B true CN101437805B (zh) 2012-05-30

Family

ID=38371048

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800162659A Expired - Fee Related CN101437805B (zh) 2006-05-11 2007-04-30 苯基氨基-苯并噁唑取代的羧酸，其生产方法及其用途

Country Status (30)

Country Link
US (2) US20090149519A1 (https=)
EP (1) EP2024347B1 (https=)
JP (1) JP2009536629A (https=)
KR (1) KR20090006846A (https=)
CN (1) CN101437805B (https=)
AR (1) AR060990A1 (https=)
AU (1) AU2007250213B2 (https=)
BR (1) BRPI0711448A2 (https=)
CA (1) CA2651660A1 (https=)
CO (1) CO6241107A2 (https=)
CY (1) CY1113177T1 (https=)
DE (1) DE102006021878A1 (https=)
DK (1) DK2024347T3 (https=)
ES (1) ES2391203T3 (https=)
HR (1) HRP20120829T1 (https=)
IL (1) IL195179A0 (https=)
MA (1) MA30402B1 (https=)
MX (1) MX2008014102A (https=)
MY (1) MY148258A (https=)
NO (1) NO20085068L (https=)
NZ (1) NZ572692A (https=)
PL (1) PL2024347T3 (https=)
PT (1) PT2024347E (https=)
RS (1) RS52450B (https=)
RU (1) RU2434003C2 (https=)
SI (1) SI2024347T1 (https=)
TW (1) TW200812987A (https=)
UY (1) UY30338A1 (https=)
WO (1) WO2007131622A1 (https=)
ZA (1) ZA200808490B (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7465804B2 (en) 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
EP1924546A1 (en) 2005-09-14 2008-05-28 Amgen, Inc Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
CA2662242C (en) 2006-09-07 2012-06-12 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
EP2064193A1 (en) 2006-09-07 2009-06-03 Amgen, Inc Heterocyclic gpr40 modulators
AU2008241490B2 (en) 2007-04-16 2011-07-21 Amgen Inc. Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid GPR40 modulators
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US8030354B2 (en) 2007-10-10 2011-10-04 Amgen Inc. Substituted biphenyl GPR40 modulators
WO2009145829A1 (en) * 2008-04-01 2009-12-03 University Of Massachusetts Type iii secretion inhibitors, analogs and uses thereof
WO2009111056A1 (en) 2008-03-06 2009-09-11 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
AU2009303475B2 (en) 2008-10-15 2012-09-13 Amgen Inc. Spirocyclic GPR40 modulators
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
CA2798330A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
US8450350B2 (en) 2010-05-05 2013-05-28 Infinity Pharmaceuticals, Inc. Triazoles as inhibitors of fatty acid synthase
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
EP2612669A4 (en) 2010-08-31 2014-05-14 Snu R&Db Foundation USING THE FÖTAL REPROGRAMMING OF A PPAR AGONIST
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
TW201317229A (zh) * 2011-09-14 2013-05-01 Daiichi Sankyo Co Ltd 稠合雜環衍生物
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US20150297573A1 (en) 2012-10-24 2015-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING Beta-CELL SURVIVAL
EP3076959B1 (en) 2013-12-04 2018-07-04 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2015119899A1 (en) 2014-02-06 2015-08-13 Merck Sharp & Dohme Corp. Antidiabetic compounds
US10426818B2 (en) 2015-03-24 2019-10-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method and pharmaceutical composition for use in the treatment of diabetes
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
CR20200347A (es) 2018-02-13 2020-09-23 Gilead Sciences Inc Inhibidores pd-1/pd-l1
TWI712412B (zh) 2018-04-19 2020-12-11 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
SG11202012425QA (en) 2018-07-13 2021-01-28 Gilead Sciences Inc Pd-1/pd-l1 inhibitors
WO2020086556A1 (en) 2018-10-24 2020-04-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
CN113784713A (zh) 2019-01-11 2021-12-10 纳吉斯制药股份有限公司 白三烯合成抑制剂

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2450042A1 (de) * 1973-10-23 1975-04-24 Lilly Industries Ltd Neue benzoxazolderivate und verfahren zu ihrer herstellung

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4025637A (en) * 1973-10-23 1977-05-24 Lilly Industries, Ltd. 2,5 OR 2,6 Disubstituted benzoxazoles
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US5296486A (en) * 1991-09-24 1994-03-22 Boehringer Ingelheim Pharmaceuticals, Inc. Leukotriene biosynthesis inhibitors
ATE188379T1 (de) * 1992-10-14 2000-01-15 Merck & Co Inc Fibrinogenrezeptor-antagonisten
EP0966465B1 (en) * 1997-03-14 2003-07-09 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
JP2002521375A (ja) * 1998-07-23 2002-07-16 アストラゼネカ アクチエボラーク 化合物
WO2000049005A1 (en) * 1999-02-16 2000-08-24 Aventis Pharma Limited Bicyclic compounds and their use as integrin receptor ligands
GB0001346D0 (en) * 2000-01-21 2000-03-08 Astrazeneca Uk Ltd Chemical compounds
JP3786203B2 (ja) * 2000-11-04 2006-06-14 アベンティス・フアーマ・リミテッド 置換アルカン酸
JP4212358B2 (ja) * 2000-12-28 2009-01-21 第一三共株式会社 Ｖｌａ−４阻害薬
JP4805552B2 (ja) * 2003-05-30 2011-11-02 武田薬品工業株式会社 縮合環化合物
GB0401334D0 (en) * 2004-01-21 2004-02-25 Novartis Ag Organic compounds
US7470712B2 (en) * 2004-01-21 2008-12-30 Bristol-Myers Squibb Company Amino-benzazoles as P2Y1 receptor inhibitors
JP2006056830A (ja) * 2004-08-20 2006-03-02 Dai Ichi Seiyaku Co Ltd ２−アリールアミノベンゾオキサゾール誘導体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2450042A1 (de) * 1973-10-23 1975-04-24 Lilly Industries Ltd Neue benzoxazolderivate und verfahren zu ihrer herstellung

Also Published As

Publication number Publication date
US20130303578A1 (en) 2013-11-14
MX2008014102A (es) 2008-11-14
HRP20120829T1 (hr) 2012-11-30
US20090149519A1 (en) 2009-06-11
MY148258A (en) 2013-03-29
PL2024347T3 (pl) 2013-01-31
WO2007131622A1 (de) 2007-11-22
TW200812987A (en) 2008-03-16
EP2024347A1 (de) 2009-02-18
CO6241107A2 (es) 2011-01-20
US8748465B2 (en) 2014-06-10
RU2008148838A (ru) 2010-06-20
IL195179A0 (en) 2009-08-03
CY1113177T1 (el) 2016-04-13
DK2024347T3 (da) 2012-10-29
NO20085068L (no) 2009-02-04
RS52450B (sr) 2013-02-28
UY30338A1 (es) 2008-01-02
HK1131978A1 (en) 2010-02-12
EP2024347B1 (de) 2012-08-01
MA30402B1 (fr) 2009-05-04
ES2391203T3 (es) 2012-11-22
AR060990A1 (es) 2008-07-30
BRPI0711448A2 (pt) 2011-11-08
AU2007250213A1 (en) 2007-11-22
JP2009536629A (ja) 2009-10-15
DE102006021878A1 (de) 2007-11-15
RU2434003C2 (ru) 2011-11-20
KR20090006846A (ko) 2009-01-15
PT2024347E (pt) 2012-10-09
SI2024347T1 (sl) 2012-11-30
CA2651660A1 (en) 2007-11-22
NZ572692A (en) 2011-03-31
CN101437805A (zh) 2009-05-20
AU2007250213B2 (en) 2013-04-11
ZA200808490B (en) 2009-10-28

Similar Documents

Publication Publication Date Title
CN101437805B (zh) 苯基氨基-苯并噁唑取代的羧酸，其生产方法及其用途
US7713988B2 (en) 4,5-diphenyl-pyrimidinylamino substituted carboxylic acids, method for the production and use thereof as medicaments
US7709490B2 (en) 4,5-diphenyl-pyrimidinyl substituted carboxylic acids, method for the production and use thereof as medicaments
US7709494B2 (en) 4,5-diphenyl-pyrimidinyl-oxy or -mercapto substituted carboxylic acids, method for the production and use thereof as medicaments
CN101535326B (zh) 被苄基取代的1,4-苯并硫杂*-1,1-二氧化物衍生物、其制备方法、含有所述化合物的药物以及其用途
US8106023B2 (en) 1,4-benzothiepin-1, 1-dioxide derivatives with improved properties method for producing the same, drugs containing said compounds and the use thereof
US8101583B2 (en) 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with fluorine, method for producing the same, drugs containing said compounds and use thereof
US8518875B2 (en) (Carboxylalkylenephenyl)phenyloxamides, method for the production thereof and use of same as a medicament
US8148375B2 (en) (Cyclopropylphenyl)phenyloxamides, method for the production thereof, and use of same as a medicament
US20080274947A1 (en) Hydroxy-Substituted Diphenylazetidinones for the Treatment of Hyperlipidemia
JP2010509380A (ja) シクロヘキシル基で置換された新規な１，４−ベンゾチエピン−１，１−ジオキシド誘導体、それらの製造方法、上記化合物を含有する薬物及びそれらの使用
HK1131978B (en) Phenylamino-benzoxazole substituted carboxylic acids, method for their production and use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1131978

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1131978

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120530

Termination date: 20140430